本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东凯普生物科技股份有限公司（以下简称"公司"）已于2023年4月15日披 露了《2022年年度报告》及其摘要。为了更好地与广大投资者进行交流，使投资 者能够进一步了解公司2022年度经营情况，公司将于2023年4月20日（星期四） 15:00—17:00在全景网举行2022年度业绩说明会。本次年度业绩说明会将采取网 络远程的方式举行，投资者可登录"全景•路演天下（https://ir.p5w.net）参 与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：董事长管乔中先生、独立董事陈英实先 生、副总经理兼董事会秘书陈毅先生、财务总监李庆辉先生。 证券代码：300639 证券简称：凯普生物 公告编号：2023-033 广东凯普生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 19日（星期三）15:00前访问https://ir.p5w.net/z ...

Financial Performance - The company's operating revenue for 2022 reached ¥5,596,971,056.72, representing a 109.39% increase compared to ¥2,673,022,953.56 in 2021[22]. - Net profit attributable to shareholders was ¥1,725,459,216.97, up 102.48% from ¥852,160,115.04 in the previous year[22]. - The net cash flow from operating activities increased by 107.37% to ¥1,309,216,063.30, compared to ¥631,341,752.94 in 2021[22]. - Basic and diluted earnings per share were both ¥3.93, reflecting a 102.58% increase from ¥1.94 in 2021[22]. - Total assets at the end of 2022 amounted to ¥6,731,125,843.21, a 59.08% increase from ¥4,231,385,338.40 at the end of 2021[22]. - The company achieved operating revenue of 5,596.97 million yuan, representing a year-on-year growth of 109.39%[45]. - The net profit attributable to shareholders reached 1,725.46 million yuan, with a year-on-year increase of 102.48%[45]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1,733.94 million yuan, reflecting a growth of 106.22% year-on-year[45]. - The company achieved a total revenue of 5,596.97 million yuan in 2022, representing a year-on-year growth of 109.39%[57]. - Net profit attributable to shareholders reached 1,725.46 million yuan, an increase of 102.48% compared to the previous year[57]. Research and Development - The company reported a significant focus on research and development in molecular diagnostics, aiming to enhance its product offerings and market competitiveness[1]. - The company has invested significantly in R&D and team development to improve laboratory testing capabilities[45]. - R&D investment increased by 104.65% year-on-year, totaling 256.27 million yuan during the reporting period[77]. - The company has established multiple innovative platforms for research and development, including gene sequencing, digital PCR, and mass spectrometry technologies[78]. - The company has developed a new method for isolating trophoblast cells from pregnant women's cervical cells, which has received a patent and will be used in prenatal screening[81]. - The company is focusing on the development of genetic testing kits, including those for G6PD gene mutations, with a validity period until March 8, 2025[133]. - The company is committed to ongoing research and development to innovate and improve its diagnostic offerings[133]. - The company has received multiple patent authorizations for its HPV treatment products, which will support its growth in the HPV detection and treatment industry[125]. - The company has established partnerships with several research institutions to enhance its R&D capabilities and product offerings[130]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies to increase its footprint in the biotechnology sector[1]. - The company aims to maximize market expansion for HPV testing products, leveraging national screening initiatives[58]. - The company is strategically positioning itself in the market by enhancing its product offerings and expanding its technological capabilities[136]. - The company is focusing on expanding its international business and developing detection products suitable for various countries and regions[185]. - The company is leveraging national health policies to target areas such as maternal and child health, birth defects, and early cancer screening, enhancing its product development and market expansion efforts[175]. - The company plans to expand its third-party medical laboratory network, with 36 laboratories expected to be operational in 2023, enhancing its position in the medical testing industry[195]. Product Development and Offerings - The company has developed a complete range of HPV testing products, with over 50 million HPV screenings conducted, and is recognized as a pioneer in cervical cancer screening in China[39]. - The company has launched a multi-level product matrix in STD testing, including the first domestic ten-pathogen simultaneous detection kit, enhancing its product offerings in infectious disease diagnostics[40]. - The company is developing clinical application test kits based on tandem mass spectrometry technology, targeting various metabolic substances for disease detection, which is expected to expand reagent sales and increase business revenue[125]. - The company has developed a series of nucleic acid testing products for cervical cancer, thalassemia, and other genetic diseases, with over 100 patents granted[99]. - The company is in the production phase for a reference product for HPV gene testing, aimed at solidifying its leading position in the HPV detection market[126]. - The company is focusing on enhancing its product offerings in the field of nucleic acid testing, which is critical for clinical diagnostics[135]. Compliance and Quality Control - The company has maintained a consistent financial reporting process, ensuring accuracy and completeness in its annual report[3]. - The company has implemented a full-process quality control management system to ensure product quality from raw material procurement to after-sales service[106]. - The company has achieved ISO13485 and ISO9001 certifications, enhancing its quality management system and optimizing resource allocation for audits[86]. - The company’s third-party medical laboratories have been certified under ISO15189, ensuring compliance with international quality management standards[87]. - The company maintained a 100% compliance rate for positive sample retesting during the COVID-19 pandemic, demonstrating rigorous quality control measures[88]. Operational Risks and Challenges - Future operational risks have been identified, and the company emphasizes the importance of investor awareness regarding these risks[3]. - The company is facing regulatory risks due to ongoing changes in industry policies and regulations, which could impact its operations if compliance is not met[200]. - The company has established strict production and management systems to mitigate potential regulatory risks and ensure compliance with industry laws[200]. Investments and Financial Management - The total investment amount for the reporting period reached CNY 196,653,699, representing a significant increase of 154.73% compared to CNY 77,200,000 in the same period last year[154]. - The company has committed to invest RMB 102.74196 million in various projects, with a cumulative investment of RMB 644.6456 million as of the reporting period[162]. - The total planned investment for the nucleic acid molecular diagnostic product industrialization project is CNY 136.23 million, with an actual investment of CNY 113.65 million, accounting for 83.42% of the planned investment[164]. - The company has not reported any significant changes in the effectiveness of the projects funded by the raised capital[162]. Corporate Social Responsibility - The company donated RMB 10 million annually to the Guangdong Provincial Basic and Applied Basic Research Fund, totaling RMB 30 million from 2021 to 2023, supporting research in public health and precision medicine[80]. - The company has established and is promoting the "Meizhou Thalassemia Prevention Model" and "Foshan Hearing Loss Gene Prevention Model" nationwide, and is developing the "Chaozhou Birth Defect Prevention Model"[199]. - The Jiangxi Provincial Government announced free prenatal and newborn disease screenings, which the company aims to leverage for growth through its advanced technology and professional services[199].

Financial Performance - The company's revenue for Q3 2022 reached ¥1,416,056,427.12, representing a 104.33% increase year-over-year[4] - Net profit attributable to shareholders was ¥509,856,393.15, a 99.24% increase compared to the same period last year[4] - The company's revenue for the first nine months of 2022 reached ¥2,654,707,613.21, an increase of 80.74% compared to ¥1,468,809,357.59 in the same period of 2021[11] - The company achieved a revenue of 4,258.58 million yuan, representing a year-on-year growth of 113.82%[16] - The net profit attributable to shareholders reached 1,488.17 million yuan, with a year-on-year increase of 130.04%[16] - The net profit after deducting non-recurring gains and losses was 1,479.87 million yuan, up 135.06% year-on-year[16] - Total operating revenue for the current period reached ¥4,258,583,892.51, a significant increase from ¥1,991,641,765.76 in the previous period, representing a growth of approximately 113.5%[30] - Net profit for the current period was ¥1,610,962,126.40, compared to ¥683,488,650.53 in the previous period, reflecting a growth of approximately 135.9%[32] - The company reported a total profit of ¥1,938,988,783.07, up from ¥809,490,780.85, which is an increase of about 139.5%[32] Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥6,399,773,306.01, reflecting a 51.25% increase from the end of the previous year[4] - The company's total liabilities increased to RMB 1.31 billion from RMB 756 million, reflecting a growth of approximately 73%[29] - The company's equity attributable to shareholders increased to RMB 4.68 billion from RMB 3.19 billion, marking a growth of approximately 47%[29] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥707,106,319.70, a 173.24% increase compared to the previous year[4] - Cash received from operating activities increased by 243.05% to ¥48,203,898.07, driven by a rise in government subsidies[11] - Cash inflow from operating activities totaled ¥2,712,767,442.45, compared to ¥1,483,641,261.22 in the previous period, indicating an increase of about 83.0%[34] - The net cash flow from investment activities was -349,243,836.93 CNY, compared to -204,577,712.64 CNY in the previous period, indicating a decline of approximately 70.5%[35] - The net cash flow from financing activities was -174,901,148.35 CNY, contrasting with a positive net flow of 113,316,648.82 CNY in the previous period[35] Research and Development - Research and development expenses rose by 99.14% to ¥159,563,544.61, indicating a significant investment in innovation[9] - The company invested 168.42 million yuan in R&D, marking a year-on-year increase of 91.32%[18] - The company has made substantial investments in research and development, focusing on women's and children's health, as part of its "Nucleic Acid 99 Strategy"[24] - The company has collaborated with various research institutions and universities to enhance its R&D capabilities and product offerings[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,125, with no preferred shareholders[13] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., holds 29.30% of the shares, totaling 128,798,878 shares[14] - The company approved a share repurchase plan with a total fund of no less than RMB 50 million and no more than RMB 100 million, with a maximum repurchase price of RMB 25.00 per share[23] Operational Highlights - The accounts receivable increased by 145.26% to ¥2,720,974,224.75, driven by the increased demand for nucleic acid testing services[8] - The company reported a significant increase in asset disposal gains, which rose by 292.20% to ¥8,140,339.64, attributed to higher gains from fixed asset disposals[10] - The total tax expenses for the first nine months of 2022 were ¥328,026,656.67, reflecting a 160.33% increase from ¥126,002,130.32, mainly due to the increase in total profit[10] - The company has established 36 third-party medical laboratories across key provinces and cities in China, with 32 currently operational[16] - The company obtained a total of 77 medical device registration/filing certificates, including 24 Class III and 7 Class II medical device registrations[18] - The company successfully acquired land use rights for the construction of the Cap Medical Science Park for 90.79 million yuan[22] Financial Challenges - Financial expenses surged by 873.46% to ¥42,934,466.20, primarily due to significant exchange rate fluctuations[9] - Credit impairment losses increased by 276.98% to ¥121,447,605.25, primarily due to the growth in revenue and increased provisions for bad debts[10] - The cash paid to employees rose by 93.65% to ¥434,544,190.14, reflecting increased salaries and bonuses[11]

Financial Performance - The company reported a revenue of 100 million RMB for the first half of 2022, representing a 20% increase compared to the same period in 2021[16]. - The company's operating revenue reached ¥2,842,527,465.39, representing a year-on-year increase of 118.89%[23]. - The net profit attributable to shareholders was ¥978,312,557.32, up 150.19% compared to the same period last year[23]. - The net profit after deducting non-recurring gains and losses was ¥969,513,706.67, reflecting a growth of 153.64% year-on-year[23]. - The company's total assets at the end of the reporting period were ¥5,799,932,854.73, an increase of 37.07% from the previous year[23]. - The company's self-produced products achieved sales revenue of CNY 531.66 million, a year-on-year increase of 46.17%[37]. - The revenue from purchased products reached CNY 105.63 million, growing by 29.51% year-on-year[37]. - The third-party medical laboratory business generated revenue of CNY 2,205.24 million, reflecting a significant year-on-year growth of 158.42%[39]. - The company achieved operating revenue of 2,842.53 million yuan, a year-on-year increase of 118.89%[49]. - Net profit attributable to shareholders reached 978.31 million yuan, up 150.19% year-on-year[49]. - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2022, representing a 25% year-over-year growth[194]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-over-year growth of 25%[196]. Research and Development - The company plans to invest 50 million RMB in R&D for new product development in the next fiscal year[16]. - The company invested ¥86,039,500 in R&D, marking a 55.97% increase year-on-year[32]. - The company emphasizes the importance of R&D in developing new technologies and products to enhance its market position[36]. - The company increased its R&D investment to 86.04 million RMB, representing a year-on-year growth of 55.97%[84]. - Research and development investments increased by 40%, totaling 200 million RMB, aimed at enhancing product offerings and technological advancements[197]. - The company has initiated over 30 new R&D projects focused on maternal and child health, with ongoing clinical trials for HPV-related drugs[60]. Product Development and Launches - The company has successfully launched a new molecular diagnostic product, which is expected to contribute significantly to revenue in the upcoming quarters[16]. - New product launches include a novel nucleic acid extraction kit, which is expected to enhance the company's market position and drive sales growth[90]. - The company has launched two new products in Q2 2022, contributing to a 15% increase in sales volume[200]. - The company is actively developing new technologies and products to enhance its diagnostic capabilities[88]. - The company has developed a range of products including fully automated nucleic acid extraction instruments and various nucleic acid detection kits for HPV and other infectious diseases[36]. - The company has developed a series of molecular diagnostic products in maternal and child health, focusing on cervical cancer HPV screening, maintaining its leadership position in the HPV testing market[55]. Market Expansion - The company has expanded its market presence in Southeast Asia, achieving a 15% market share in the region[16]. - Market expansion efforts are underway, targeting Southeast Asia, with plans to establish partnerships with local distributors by Q4 2022[90]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[196]. - The company is exploring potential acquisitions to enhance its product portfolio, focusing on companies with complementary technologies[89]. Operational Efficiency - The company is enhancing its production capacity and digital transformation to support the upstream and downstream supply chain[61]. - The company has implemented a Manufacturing Execution System (MES) to ensure real-time interaction and quality control during the production process[62]. - A new strategy has been implemented to improve supply chain efficiency, aiming to reduce costs by 15% over the next year[90]. - The company is implementing a new technology platform aimed at improving operational efficiency, projected to reduce costs by 10% annually[194]. Regulatory and Compliance - The company is facing potential risks related to regulatory changes in the healthcare sector, which may impact future operations[3]. - The company has established a strict production and operational management system to comply with regulatory requirements and mitigate risks associated with industry policies and regulations[148]. - The company has received regulatory approval for multiple new diagnostic kits, including the Hepatitis B virus nucleic acid test kit, which is valid until March 1, 2025[88]. Corporate Governance and Social Responsibility - The company has established a comprehensive governance structure, updating various internal regulations to enhance corporate governance and protect shareholder rights[173]. - The company has committed to donating RMB 10 million annually from 2021 to 2023 to support the Guangdong Provincial Basic and Applied Basic Research Fund, totaling RMB 30 million over three years[183]. - The company has actively engaged in social welfare activities, donating over RMB 1.2 million to poverty alleviation projects and supporting educational initiatives[182]. - The company has maintained a commitment to environmental protection, being recognized multiple times as a "Clean Production Enterprise" in Guangdong Province[179]. Shareholder Returns - No cash dividends or stock bonuses will be distributed to shareholders for the current fiscal year[4]. - The company plans to distribute cash dividends amounting to no less than 10% of the distributable profit achieved in the current year[190]. - A cash dividend of 0.5 RMB per share was announced, reflecting the company's commitment to returning value to shareholders[197].

Financial Performance - The company's revenue for Q1 2022 reached ¥1,510,718,034.62, representing a 147.87% increase compared to ¥609,471,858.80 in the same period last year[4] - Net profit attributable to shareholders was ¥499,725,567.45, a 190.64% increase from ¥171,939,617.11 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥491,776,771.95, up 201.55% from ¥163,082,987.01 in the previous year[4] - Basic earnings per share increased to ¥1.72, a rise of 196.55% from ¥0.58 in the previous year[4] - Total operating revenue for the current period reached ¥1,510,718,034.62, a significant increase from ¥609,471,858.80 in the previous period, representing a growth of approximately 147.5%[42] - Net profit for the current period was ¥551,717,509.33, compared to ¥188,197,415.46 in the previous period, reflecting an increase of approximately 194.0%[43] - Basic and diluted earnings per share were both ¥1.72, up from ¥0.58 in the previous period, marking an increase of approximately 196.6%[44] Cash Flow and Investments - The net cash flow from operating activities was ¥119,282,306.10, a significant improvement of 339.07% compared to a negative cash flow of ¥49,894,766.64 in the same period last year[4] - Cash flow from operating activities generated a net amount of ¥119,282,306.10, a turnaround from a negative cash flow of ¥49,894,766.64 in the previous period[45] - Cash received from investment decreased significantly by 58.68% to ¥611,800,000.00 from ¥1,480,606,837.73, mainly due to a reduction in the recovery of matured financial products[16] - The company invested ¥497,600,000.00 in cash during the period, a decrease of 63.01% compared to ¥1,345,200,000.00, reflecting reduced investment in financial products[16] - Investment activities resulted in a net cash outflow of ¥-52,701,101.43, contrasting with a net inflow of ¥42,290,234.91 in the previous period[46] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥5,137,517,950.16, reflecting a 21.41% increase from ¥4,231,385,338.40 at the end of the previous year[4] - The total assets of the company reached ¥5.14 billion, up from ¥4.23 billion, reflecting a growth of about 21.5%[40] - The company's total liabilities increased to ¥1.11 billion from ¥756.37 million, an increase of approximately 46.7%[40] - The company's retained earnings grew to ¥2.08 billion from ¥1.58 billion, an increase of about 31.6%[40] Operational Highlights - Revenue from self-produced products was RMB 274.72 million, an increase of 47.17% year-on-year, while revenue from purchased products decreased by 25.49% to RMB 40.18 million[24] - The company has established 37 third-party medical laboratories across key provinces and cities, with 30 of them operational, contributing to a medical testing service revenue of RMB 1,195.82 million, a growth of 224.17%[25] - The company won a bid to establish a third-party medical testing laboratory in Foshan, which will have a daily testing capacity of 10,000 samples under normal conditions and 100,000 during emergencies[26] - The company received a medical device production license for its wholly-owned subsidiary, enhancing its operational capabilities[36] - The company is conducting Phase II clinical trials for its newly developed drug "Chloroquine Phosphate Gel," which is currently under evaluation for safety and efficacy[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,877, with no preferred shareholders[18] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., holds 29.22% of the shares, totaling 85,865,919 shares[18] - The company’s repurchase account held 2,649,200 shares, representing 0.90% of total shares, ranking ninth among all shareholders[20] Research and Development - The company invested RMB 32.06 million in R&D, marking a 10.31% increase compared to the previous year[24] - The company obtained 9 new patents during the reporting period, including 4 invention patents and 1 Australian invention patent[33] Tax and Expenses - The income tax expense for Q1 2022 was ¥119,285,611.97, a 208.98% increase from ¥38,606,510.08 in the same period last year, driven by higher profitability[13] - Cash paid to employees increased by 71.51% to ¥134,265,895.46 from ¥78,283,851.82, mainly due to higher salaries and bonuses[16] - Cash paid for various taxes rose by 49.04% to ¥53,838,498.43 from ¥36,124,476.59, attributed to increased VAT and income tax payments[16] Currency Exchange Impact - The company experienced a significant currency exchange impact, with cash and cash equivalents affected by ¥-5,243,050.81, a 626.26% increase in negative impact compared to ¥-721,923.35 in the previous year, due to substantial appreciation of the RMB[16] - The company experienced a foreign exchange loss of ¥-5,243,050.81, compared to a loss of ¥-721,923.35 in the previous period, indicating increased volatility in currency exchange rates[46]

Financial Performance - The company's operating revenue for 2021 was ¥2,673,022,953.56, representing a 97.34% increase compared to ¥1,354,496,759.29 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥852,160,115.04, a 134.97% increase from ¥362,662,411.14 in 2020[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥840,818,919.67, up 138.15% from ¥353,056,537.12 in 2020[19]. - The company's total assets at the end of 2021 were ¥4,231,385,338.40, an increase of 48.11% from ¥2,856,964,272.70 at the end of 2020[19]. - The basic earnings per share for 2021 was ¥2.91, reflecting an increase of 118.80% compared to ¥1.33 in 2020[19]. - The weighted average return on equity for 2021 was 30.32%, up from 20.70% in 2020, indicating a 9.62% increase[19]. - The company achieved a revenue of 2,673.02 million yuan, representing a year-on-year growth of 97.34%[43]. - The net profit attributable to shareholders reached 852.16 million yuan, with a year-on-year increase of 134.97%[43]. - Total operating revenue for the reporting period reached 2,673.02 million yuan, a year-on-year growth of 97.34%[56]. - Net profit attributable to shareholders was 852.16 million yuan, reflecting a year-on-year increase of 134.97%[56]. Market Expansion and Product Development - The company is focused on expanding its market presence and enhancing its product offerings in the field of in vitro diagnostics[11]. - The company has established 35 third-party medical laboratories across key cities in China, with 30 already operational[42]. - The company is focused on expanding its market presence through the development of new technologies and products in the molecular diagnostics field[49]. - The company has launched multiple new nucleic acid detection kits, including those for COVID-19 and other infectious diseases[48]. - The company is actively engaged in research and development to enhance its diagnostic capabilities and product effectiveness[48]. - The company is focusing on maximizing its market share in the HPV testing and treatment sectors through strategic product development and international registrations[91]. - The company is developing integrated diagnostic solutions for birth defect prevention, including thalassemia gene testing and STD detection products[65]. - The company is expanding its product line to include a new COVID-19 nucleic acid testing kit, expected to be available by April 8, 2026[99]. - The company is actively developing new products, including fully automated nucleic acid extraction systems and various PCR kits, to expand its market presence[102]. Research and Development - The company invested 125.22 million yuan in R&D, marking a 52.39% increase compared to the previous year[42]. - The company has a strong focus on innovation, with 79 patents granted, including 36 invention patents[42]. - The company has established a strong R&D team with 33 PhDs and 176 Master's degree holders, focusing on continuous innovation and product development[73]. - The company aims to enhance its R&D capabilities in molecular diagnostics, focusing on various disease detection products, including HPV and congenital deafness, to strengthen its market position[143]. - The company has initiated research on enzyme raw materials to prepare for domestic alternatives, which will help reduce costs and improve product profitability[92]. - The company is developing a new type of flow cytometry technology for clinical applications, with a focus on prenatal screening and diagnosis[95]. - The company has received approval for 20 new medical testing kits, including tests for Chlamydia, Mycoplasma, and various genetic conditions, with expected market entry dates ranging from 2024 to 2026[98][99]. Operational Efficiency and Cash Flow - The company experienced a significant increase in cash flow from operating activities, with a net cash flow of ¥631,341,752.94, a 102.81% increase from ¥311,300,240.80 in 2020[19]. - Total cash inflow from operating activities increased by 86.53% to CNY 2,227,854,942.90, primarily due to increased cash received from sales of goods and services[106]. - Net cash flow from operating activities rose by 102.81% to CNY 631,341,752.94, reflecting improved operational efficiency[106]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 20%[100]. - The gross margin for the year was reported at 60%, reflecting improved cost management and operational efficiencies[100]. Corporate Governance and Management - The company held 4 shareholder meetings during the reporting period, ensuring compliance with relevant laws and regulations, and guaranteeing equal rights for all shareholders, especially minority shareholders[159]. - A total of 13 board meetings were conducted, with all decisions made in accordance with legal procedures, reflecting the board's commitment to the interests of the company and its shareholders[160]. - The supervisory board convened 11 meetings, effectively overseeing the company's financial status and ensuring compliance by directors and senior management[160]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations, ensuring no conflicts of interest[161]. - The company has established an independent financial accounting system, enabling it to make autonomous financial decisions without shared bank accounts with controlling shareholders[162]. - The company has a total of 13 directors and supervisors, with the majority not receiving remuneration from related parties[180]. - The company has established a remuneration decision-making process based on the Company Law and its Articles of Association, ensuring transparency and accountability[179]. Industry Trends and Challenges - The molecular diagnostics industry is experiencing rapid growth due to increased demand for nucleic acid testing driven by the COVID-19 pandemic[30]. - The independent medical laboratory market is expected to continue growing due to increasing outsourcing penetration driven by tiered diagnosis and treatment and cost control pressures in hospitals[32]. - The molecular diagnostics sector is expected to continue its rapid growth, driven by increasing healthcare spending and the ongoing demand for nucleic acid testing[136]. - The molecular diagnostics industry is experiencing intensified competition, with an increase in the number of laboratories capable of conducting nucleic acid testing, necessitating continuous innovation and product development to maintain competitive advantage[151]. - As the company expands its business into medical laboratory testing, it faces increased management risks that require timely adjustments to its management systems and practices[153].

Financial Performance - The company's revenue for Q3 2021 reached ¥693,008,112.93, representing a 68.50% increase year-over-year[4] - Net profit attributable to shareholders was ¥255,901,368.29, up 77.33% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥247,329,518.28, reflecting a 76.49% increase year-over-year[4] - The company achieved a revenue of CNY 1,991.64 million for the first three quarters of 2021, representing a year-on-year growth of 117.23%[18] - The net profit attributable to shareholders for the same period was CNY 646.92 million, an increase of 136.71% year-on-year[18] - In Q3 2021, the company reported a revenue of CNY 693.01 million, reflecting a year-on-year growth of 68.50%[18] - The net profit attributable to shareholders in Q3 2021 was CNY 255.90 million, up 77.33% compared to the same quarter last year[18] - The net profit for Q3 2021 was CNY 683,488,650.53, a significant increase of 128.5% compared to CNY 299,415,923.83 in Q3 2020[28] - The total profit for Q3 2021 was CNY 809,490,780.85, a substantial increase of 130.0% from CNY 352,062,786.73 in Q3 2020[28] - The total revenue from operating activities reached CNY 1,483,641,261.22, up from CNY 748,276,022.72 in the same period last year, indicating a growth of 98.2%[31] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥3,947,055,007.07, a 38.16% increase from the end of the previous year[4] - Total current assets amounted to ¥1,962,126,206.56 as of December 31, 2020[34] - Non-current assets totaled ¥894,838,066.14, contributing to a total asset value of ¥2,856,964,272.70[35] - Total current liabilities reached ¥303,021,737.91, with short-term borrowings at ¥75,272,240.00 and accounts payable at ¥86,199,861.84[36] - Total liabilities were reported at ¥322,685,997.69, while total equity stood at ¥2,534,278,275.01[36] Cash Flow - The operating cash flow for the year-to-date period was ¥258,782,373.78, showing a 113.07% increase[4] - Cash received from sales and services increased by 103.94% to CNY 1,468.81 million, driven by higher operating income[12] - The company's cash outflow for purchasing goods and services rose by 182.92% to CNY 602.11 million, reflecting increased procurement of products and raw materials[12] - The cash flow from operating activities generated a net amount of CNY 258,782,373.78, compared to CNY 121,454,522.72 in the previous year, marking a growth of 112.7%[31] - Investment activities resulted in a net cash outflow of CNY 204,577,712.64, an improvement from a net outflow of CNY 271,693,295.44 in the same period last year[31] - The cash and cash equivalents at the end of the period stood at CNY 557,855,554.71, down from CNY 1,170,439,588.04 at the end of Q3 2020[32] Expenses - Research and development expenses increased by 84.52% to CNY 80.12 million due to higher salaries and materials costs[11] - Sales expenses rose by 31.15% to CNY 269.28 million, primarily due to increased marketing costs associated with revenue growth[11] - The company has invested heavily in R&D, with expenses amounting to CNY 80,124,533.38 for the current period, compared to CNY 43,422,241.05 in the previous period[27] Investments and Expansion - The company has made a 100% investment in Guangzhou Yingzan Biotechnology Co., Ltd., reflecting its strategy for market expansion[9] - The company has established multiple R&D innovation platforms, including a provincial-level HPV-related disease molecular diagnostic engineering technology research center and a postdoctoral research workstation[19] - The company has accelerated the construction of third-party medical laboratories, establishing 35 laboratories across various cities, with 24 already obtaining medical institution practice licenses[20] - The company has established a nationwide third-party testing service network, gradually forming a comprehensive service capability[20] Recognition and Innovation - The company has been recognized as a "National Technology Innovation Demonstration Enterprise" by the Ministry of Industry and Information Technology, which is expected to positively impact future innovation[19] - As of now, the company has obtained a total of 71 patent certificates, including 34 invention patents, and has registered 69 medical device products, with 23 classified as Class III medical devices[19] Other Information - The company reported an investment income of CNY 138.03 million, a significant increase of 273.96% attributed to higher financial management returns[11] - The company reported an increase in investment income to CNY 13,802,611.54 from CNY 3,690,964.07, which is a growth of 274.5%[28] - The company has implemented new leasing standards effective January 1, 2021, without impacting prior financial results[37] - The report for the third quarter of 2021 was not audited, indicating a preliminary financial status[39]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,298,633,652.83, representing a 156.88% increase compared to CNY 505,537,512.64 in the same period last year[21]. - The net profit attributable to shareholders of the listed company reached CNY 391,020,901.99, a significant increase of 203.15% from CNY 128,985,345.14 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 382,246,481.34, up 205.94% from CNY 124,940,856.93 in the same period last year[21]. - The basic earnings per share increased to CNY 1.33, a rise of 171.43% compared to CNY 0.49 in the previous year[21]. - The total assets at the end of the reporting period were CNY 3,544,164,857.98, reflecting a 24.05% increase from CNY 2,856,964,272.70 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company were CNY 2,654,878,006.91, an increase of 11.06% from CNY 2,390,534,390.08 at the end of the previous year[21]. - The net cash flow from operating activities was CNY 7,417,637.98, which decreased by 82.45% compared to CNY 42,271,345.34 in the same period last year[21]. - The weighted average return on net assets increased by 5.10 percentage points to 15.39% from 10.29% in the previous year[21]. Business Operations and Market Position - The company has developed a series of nucleic acid detection products widely used in clinical diagnosis and public health, establishing a strong market position in cervical cancer screening[28]. - The company has obtained 81 medical device product registrations, including 23 Class III medical device certificates[30]. - The sales revenue from self-produced products was 363.73 million CNY, an increase of 64.28% year-on-year, while revenue from purchased products grew by 95.64% to 81.56 million CNY[30]. - The company has established 32 third-party medical laboratories across the country, with 22 already in operation, enhancing its service network[28]. - The company actively participated in COVID-19 prevention efforts, leading to rapid growth in its nucleic acid testing business during the pandemic[28]. - The company has a strong R&D team with 36 PhDs and 147 master's degree holders, supporting its innovation capabilities[28]. - The company holds 67 patents, including 33 domestic invention patents, enhancing its competitive edge in the market[28]. Research and Development - The company increased its R&D investment to ¥55.16 million, a year-on-year growth of 75.83%, focusing on molecular diagnostics in women's and children's health[48]. - The company has introduced over 30 new R&D projects, primarily in the field of maternal and child health, aiming to enhance clinical registration and rapid deployment of new testing technologies[50]. - The company is focusing on high-end specialty tests such as tumor gene testing and high-density gene chips as part of its growth strategy[35]. - The company is developing innovative products in respiratory virus detection, including COVID-19 and influenza tests, as part of its response to the pandemic[49]. - The company is focused on developing new diagnostic technologies for tumors and infectious diseases[68]. Strategic Initiatives and Future Outlook - The company plans to enhance its online sales platform, aiming for a 20% increase in e-commerce revenue by the end of 2021[73]. - The company is actively pursuing strategic acquisitions, with plans to acquire a smaller biotech firm to enhance its R&D capabilities by Q4 2021[72]. - Market expansion plans include entering two new international markets by the end of 2021, which are projected to increase overall market share by 15%[173]. - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 30% compared to the first half, aiming for a total revenue of approximately 1.95 billion RMB[174]. Corporate Governance and Compliance - The company emphasizes the quality and timeliness of information disclosure, adhering to principles of transparency and fairness[145]. - The company has maintained strict compliance with commitments made since its listing, with no violations or delays reported[148]. - The company has established detailed regulations regarding related party transactions to ensure fairness and transparency in decision-making processes[165]. - The company emphasizes compliance with regulatory policies and has established a risk prevention mechanism to address potential industry policy and regulatory risks[126]. Community Engagement and Social Responsibility - The company has contributed a total of RMB 317,087.50 in public welfare donations during the reporting period, supporting various charitable activities[153]. - The company established the "Yuechao Women's and Children's Cultural Charity Foundation," donating RMB 321,000 to assist 100 impoverished women in Chaozhou[152]. - The company has been recognized for its contributions to poverty alleviation, receiving honors for its charitable activities in 2020 and 2021[153].

Financial Performance - The company's operating revenue for Q1 2021 was CNY 609,471,858.80, representing a 307.09% increase compared to CNY 149,713,684.31 in the same period last year [7] - The net profit attributable to shareholders for Q1 2021 reached CNY 171,939,617.11, a significant increase of 771.05% from CNY 19,739,403.97 in the previous year [7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 163,082,987.01, up 826.50% from CNY 17,602,137.14 year-on-year [7] - The basic earnings per share for Q1 2021 was CNY 0.73, which is a 711.11% increase compared to CNY 0.09 in the same period last year [7] - The company reported a net cash flow from operating activities of CNY -49,894,766.64, which is a 104.00% decrease compared to CNY -24,458,088.61 in the previous year [7] - The company achieved a revenue of 609.47 million yuan, representing a year-on-year growth of 307.09% [19] - The net profit attributable to shareholders reached 171.94 million yuan, with a year-on-year increase of 771.05% [19] - The company's net profit for Q1 2021 reached CNY 188,197,415.46, a significant increase from CNY 24,759,408.12 in the same period last year, representing a growth of approximately 659% [53] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,229,178,523.58, reflecting a 13.03% increase from CNY 2,856,964,272.70 at the end of the previous year [7] - The net assets attributable to shareholders at the end of the reporting period were CNY 2,580,980,089.10, an increase of 7.97% from CNY 2,390,534,390.08 at the end of the previous year [7] - Total liabilities rose to CNY 490,364,844.50, compared to CNY 322,685,997.69 in the previous year, indicating increased leverage [46] - The total equity attributable to shareholders increased to CNY 2,580,980,089.10 from CNY 2,390,534,390.08, showing growth in shareholder value [46] - The company's total assets as of March 31, 2021, are 3,229,178,523.58 RMB, an increase from 2,856,964,272.70 RMB at the end of 2020 [44] Revenue Sources - Revenue for Q1 2021 reached CNY 609.47 million, a 307.09% increase compared to CNY 149.71 million in Q1 2020, driven by increased demand for nucleic acid testing and expanded medical laboratory services [16] - The revenue from self-produced nucleic acid testing reagents, instruments, and consumables was 186.66 million yuan, up 214.71% year-on-year [21] - The revenue from third-party medical testing services was 368.88 million yuan, reflecting a year-on-year growth of 344.16% [20] Research and Development - R&D expenses increased by 112.62% to CNY 26.63 million, reflecting higher personnel costs and research material expenses [16] - The company invested 29.07 million yuan in R&D, marking a 121.93% increase compared to the previous year [21] - Research and development expenses for the quarter were CNY 3,483,090.81, significantly higher than CNY 1,244,692.52 in the same period last year, indicating a focus on innovation and product development [56] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,621 [10] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., held 29.15% of the shares, totaling 68,615,200 shares [10] - The company plans to distribute a cash dividend of CNY 2.50 per 10 shares, totaling CNY 58.5 million, and to increase capital stock by 2.5 shares for every 10 shares held, resulting in an additional 58.5 million shares [30] Cash Flow - Cash received from sales of goods and services was CNY 353.40 million, a 164.05% increase from CNY 133.84 million in the same period last year [17] - The company reported a decrease in other comprehensive income, which was -CNY 5,449,781.33 compared to -CNY 7,629,562.13 in the previous year [46] - The ending balance of cash and cash equivalents was 403,693,371.86 CNY, up from 301,068,278.71 CNY in the previous period, indicating improved liquidity [62] Strategic Initiatives - The company actively participated in pandemic prevention efforts, contributing to rapid business growth in its medical laboratory services [18] - The company plans to continue expanding its R&D capabilities and product offerings to strengthen its competitive position in the market [23] - The company is focused on expanding its third-party medical laboratory operations to improve profitability and ensure stable revenue growth [25] - The company aims to strengthen its market position and increase market share through enhanced marketing and after-sales services [25] Compliance and Governance - The company has not reported any non-compliance with external guarantees during the reporting period [37] - There were no significant changes in the feasibility of projects or any non-operational fund occupation by controlling shareholders during the reporting period [38] - The company has no outstanding commitments from its actual controllers or shareholders that have not been fulfilled during the reporting period [33]

Financial Performance - In 2020, the company's operating revenue reached RMB 1.354 billion, an increase of 85.70% year-on-year[4]. - The net profit attributable to shareholders was RMB 363 million, up 146.22% year-on-year, with a net profit of RMB 353 million after deducting non-recurring gains and losses, representing a growth of 160.87%[4]. - The net cash flow from operating activities was RMB 311 million, reflecting a year-on-year increase of 175.90%[4]. - The company's operating revenue for 2020 was approximately ¥1.35 billion, representing an increase of 85.70% compared to ¥729.39 million in 2019[30]. - The net profit attributable to shareholders for 2020 was approximately ¥362.66 million, a significant increase of 146.22% from ¥147.29 million in 2019[30]. - The basic earnings per share for 2020 was ¥1.66, reflecting a growth of 137.14% compared to ¥0.70 in 2019[31]. - The total assets of the company at the end of 2020 were approximately ¥2.86 billion, an increase of 120.28% from ¥1.30 billion at the end of 2019[31]. - The weighted average return on equity for 2020 was 20.70%, an increase from 14.49% in 2019[31]. - The company achieved total revenue of 1.354 billion yuan, an increase of 85.70% year-on-year[51]. - Net profit reached 394.66 million yuan, up 188.16% compared to the previous year[51]. Product Development and Innovation - The company developed a COVID-19 detection kit within nine days, achieving performance testing results consistent with leading industry standards[5]. - The company invested RMB 409 million in the research and development of nucleic acid molecular diagnostic products, ensuring sufficient funding for future projects[7]. - The company has developed a series of nucleic acid testing products, including HPV detection kits and thalassemia gene testing kits, widely used in clinical testing and population screening[40]. - The company is focused on expanding its product line in genetic disease testing, including tests for Mediterranean anemia and deafness susceptibility genes[41]. - The company has launched new molecular diagnostic instruments, including various models of nucleic acid hybridization instruments and automated extraction devices[42]. - The company has developed three COVID-19 nucleic acid testing products, including PCR-fluorescence probe and Sanger sequencing methods[75]. - The company introduced several new products, including a fully automated nucleic acid extraction and purification instrument (HBNP-9600A) and various nucleic acid extraction kits, enhancing its product portfolio for clinical applications[123]. Market Expansion and Strategic Partnerships - The company plans to expand its third-party medical laboratory network to 50 locations nationwide, with 30 expected to be operational this year[9]. - A strategic partnership was formed with Hunan Youzhe Technology, holding a 20% stake, to develop an intelligent detection system for gynecological microecological analysis[14]. - The company has established a nationwide network of third-party medical laboratories, with 19 already licensed, enhancing its medical testing service capabilities[67]. - The company aims to achieve comprehensive coverage of nucleic acid molecular diagnostic products in the domestic market within 3-5 years, focusing on HPV testing and other key diagnostic products[159]. - The company is exploring potential mergers and acquisitions to accelerate growth and expand its technological capabilities in the biotechnology sector[120]. Research and Development - The company invested 60 million RMB in a key domestic supplier and holds a 2.73% stake in Hangzhou Borui Technology Co., Ltd., a fluorescent PCR instrument manufacturer[14]. - R&D investment reached 82.17 million RMB, a year-on-year increase of 32.83%[75]. - The number of R&D personnel increased to 358 in 2020, representing 21.80% of the total workforce, up from 18.73% in 2019[117]. - The company is committed to continuous innovation in product development and technology to enhance its market position[40]. - The company plans to increase R&D investment and accelerate new product development to enhance its competitive position in the rapidly growing nucleic acid molecular diagnostic market[116]. Operational Capacity and Infrastructure - The production scale of the headquarters in Chaozhou increased fourfold, expanding from 1,800 square meters to 7,100 square meters[13]. - Daily production capacity for hybridization reagents and fluorescent PCR reagents reached 200,000 tests, with nucleic acid extraction and sample preservation solutions also achieving a daily capacity of 200,000 units each[13]. - By 2021, the company plans to increase daily production capacity for extraction reagents to 1 million and for sample preservation solutions to 500,000 based on market demand[13]. - The company has constructed and upgraded laboratory spaces exceeding 26,000 square meters to support its integrated business model of "nucleic acid testing products + medical testing services"[85]. Financial Management and Profit Distribution - The profit distribution plan approved by the board includes a cash dividend of 2.5 RMB per 10 shares and a capital reserve conversion of 2.5 shares per 10 shares[17]. - The total distributable profit at the end of the reporting period was RMB 257.81 million, with the cash dividend representing 100% of the profit distribution[186]. - The company has maintained a consistent cash dividend policy over the past three years, with cash dividends of RMB 58.51 million in 2020, RMB 42.49 million in 2019, and RMB 44.27 million in 2018[187]. - The company has committed to a stable profit distribution policy, ensuring that cash dividends account for at least 10% of the distributable profits each year[194]. Industry Trends and Market Dynamics - The molecular diagnostic sector is experiencing rapid growth, with a compound annual growth rate of 31.63% in China's market from 2013 to 2019[54]. - The COVID-19 pandemic has significantly boosted the demand for nucleic acid testing, presenting a major opportunity for the molecular diagnostics industry[156]. - Increased competition in the molecular diagnostics market is anticipated, prompting the company to focus on new product development, technological innovation, and enhancing its competitive edge[171]. - The independent clinical laboratory (ICL) sector in China grew from 89 ICLs in 2010 to 1,568 by March 2020, with a compound annual growth rate exceeding 30%[58]. Compliance and Governance - The company is committed to maintaining compliance with the Shenzhen Stock Exchange's disclosure requirements for medical device businesses[118]. - The company has established regulations to ensure fair decision-making in related transactions to protect shareholder interests[199]. - The board of directors has committed to strictly follow the company's articles of association regarding related transactions[199].